Cargando…

Simvastatin and Losartan Differentially and Synergistically Inhibit Atherosclerosis in Apolipoprotein E(-/-) Mice

BACKGROUND AND OBJECTIVES: Since statins and angiotensin receptor blockers are a frequently prescribed combination in patients with atherosclerotic cardiovascular diseases, we tested the interactive effects of simvastatin and losartan on atherosclerosis in apolipoprotein E (apoE)(-/-) mice. MATERIAL...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Bok-Soo, Choi, Jin Yong, Kim, Joo Yun, Han, Seul Hee, Park, Jeong Euy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Society of Cardiology 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3438264/
https://www.ncbi.nlm.nih.gov/pubmed/22977450
http://dx.doi.org/10.4070/kcj.2012.42.8.543
_version_ 1782242893363150848
author Lee, Bok-Soo
Choi, Jin Yong
Kim, Joo Yun
Han, Seul Hee
Park, Jeong Euy
author_facet Lee, Bok-Soo
Choi, Jin Yong
Kim, Joo Yun
Han, Seul Hee
Park, Jeong Euy
author_sort Lee, Bok-Soo
collection PubMed
description BACKGROUND AND OBJECTIVES: Since statins and angiotensin receptor blockers are a frequently prescribed combination in patients with atherosclerotic cardiovascular diseases, we tested the interactive effects of simvastatin and losartan on atherosclerosis in apolipoprotein E (apoE)(-/-) mice. MATERIALS AND METHODS: Apolipoprotein E(-/-) mice were fed a high-fat, high-cholesterol (HFHC) diet for 12 weeks, with and without simvastatin (40 mg/kg) and/or losartan (20 mg/kg). The mice were divided into 5 groups and were fed as follows: regular chow (control diet, n=5), HFHC diet (n=6), HFHC diet with losartan (n=6), HFHC diet with simvastatin (n=6), and HFHC diet with both losartan and simvastatin (n=6). RESULTS: Losartan treatment in apoE(-/-) mice significantly decreased atherosclerotic lesion areas in whole aortic strips stained with Oil Red O. The plaque area measured at the aortic sinus level was reduced significantly by 17% (HFHC; 346830.9±52915.8 µm(2) vs. HFHC plus losartan; 255965.3±74057.7 µm(2), p<0.05) in the losartan-treated group. Simvastatin and simvastatin plus losartan treatments reduced macrophage infiltration into lesions by 33% (HFHC; 183575.6±43211.2 µm(2) vs. HFHC plus simvastatin; 120556.0±39282.8 µm(2), p<0.05) and 44% (HFHC; 183575.6±43211.2 µm(2) vs. HFHC plus simvastatin and losartan; 103229.0±8473.3 µm(2), p<0.001, respectively). In mice fed the HFHC diet alone, the smooth muscle cell layer in the aortic media was almost undetectable. In mice co-treated with losartan and simvastatin, the smooth muscle layer was more than 60% preserved (p<0.05). Given alone, losartan showed a slightly stronger effect than simvastatin; however, treatment with losartan plus simvastatin induced a greater inhibitory effect on atherosclerosis than either drug given alone. Serum lipid profiles did not differ significantly among the groups. CONCLUSION: Losartan displayed anti-atherosclerotic effects in apoE(-/-) mice that were equivalent to or greater than the effects of simvastatin. Combined treatment with these drugs had greater effect than either drug alone.
format Online
Article
Text
id pubmed-3438264
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher The Korean Society of Cardiology
record_format MEDLINE/PubMed
spelling pubmed-34382642012-09-13 Simvastatin and Losartan Differentially and Synergistically Inhibit Atherosclerosis in Apolipoprotein E(-/-) Mice Lee, Bok-Soo Choi, Jin Yong Kim, Joo Yun Han, Seul Hee Park, Jeong Euy Korean Circ J Original Article BACKGROUND AND OBJECTIVES: Since statins and angiotensin receptor blockers are a frequently prescribed combination in patients with atherosclerotic cardiovascular diseases, we tested the interactive effects of simvastatin and losartan on atherosclerosis in apolipoprotein E (apoE)(-/-) mice. MATERIALS AND METHODS: Apolipoprotein E(-/-) mice were fed a high-fat, high-cholesterol (HFHC) diet for 12 weeks, with and without simvastatin (40 mg/kg) and/or losartan (20 mg/kg). The mice were divided into 5 groups and were fed as follows: regular chow (control diet, n=5), HFHC diet (n=6), HFHC diet with losartan (n=6), HFHC diet with simvastatin (n=6), and HFHC diet with both losartan and simvastatin (n=6). RESULTS: Losartan treatment in apoE(-/-) mice significantly decreased atherosclerotic lesion areas in whole aortic strips stained with Oil Red O. The plaque area measured at the aortic sinus level was reduced significantly by 17% (HFHC; 346830.9±52915.8 µm(2) vs. HFHC plus losartan; 255965.3±74057.7 µm(2), p<0.05) in the losartan-treated group. Simvastatin and simvastatin plus losartan treatments reduced macrophage infiltration into lesions by 33% (HFHC; 183575.6±43211.2 µm(2) vs. HFHC plus simvastatin; 120556.0±39282.8 µm(2), p<0.05) and 44% (HFHC; 183575.6±43211.2 µm(2) vs. HFHC plus simvastatin and losartan; 103229.0±8473.3 µm(2), p<0.001, respectively). In mice fed the HFHC diet alone, the smooth muscle cell layer in the aortic media was almost undetectable. In mice co-treated with losartan and simvastatin, the smooth muscle layer was more than 60% preserved (p<0.05). Given alone, losartan showed a slightly stronger effect than simvastatin; however, treatment with losartan plus simvastatin induced a greater inhibitory effect on atherosclerosis than either drug given alone. Serum lipid profiles did not differ significantly among the groups. CONCLUSION: Losartan displayed anti-atherosclerotic effects in apoE(-/-) mice that were equivalent to or greater than the effects of simvastatin. Combined treatment with these drugs had greater effect than either drug alone. The Korean Society of Cardiology 2012-08 2012-08-31 /pmc/articles/PMC3438264/ /pubmed/22977450 http://dx.doi.org/10.4070/kcj.2012.42.8.543 Text en Copyright © 2012 The Korean Society of Cardiology http://creativecommons.org/licenses/by-nc/3.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Lee, Bok-Soo
Choi, Jin Yong
Kim, Joo Yun
Han, Seul Hee
Park, Jeong Euy
Simvastatin and Losartan Differentially and Synergistically Inhibit Atherosclerosis in Apolipoprotein E(-/-) Mice
title Simvastatin and Losartan Differentially and Synergistically Inhibit Atherosclerosis in Apolipoprotein E(-/-) Mice
title_full Simvastatin and Losartan Differentially and Synergistically Inhibit Atherosclerosis in Apolipoprotein E(-/-) Mice
title_fullStr Simvastatin and Losartan Differentially and Synergistically Inhibit Atherosclerosis in Apolipoprotein E(-/-) Mice
title_full_unstemmed Simvastatin and Losartan Differentially and Synergistically Inhibit Atherosclerosis in Apolipoprotein E(-/-) Mice
title_short Simvastatin and Losartan Differentially and Synergistically Inhibit Atherosclerosis in Apolipoprotein E(-/-) Mice
title_sort simvastatin and losartan differentially and synergistically inhibit atherosclerosis in apolipoprotein e(-/-) mice
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3438264/
https://www.ncbi.nlm.nih.gov/pubmed/22977450
http://dx.doi.org/10.4070/kcj.2012.42.8.543
work_keys_str_mv AT leeboksoo simvastatinandlosartandifferentiallyandsynergisticallyinhibitatherosclerosisinapolipoproteinemice
AT choijinyong simvastatinandlosartandifferentiallyandsynergisticallyinhibitatherosclerosisinapolipoproteinemice
AT kimjooyun simvastatinandlosartandifferentiallyandsynergisticallyinhibitatherosclerosisinapolipoproteinemice
AT hanseulhee simvastatinandlosartandifferentiallyandsynergisticallyinhibitatherosclerosisinapolipoproteinemice
AT parkjeongeuy simvastatinandlosartandifferentiallyandsynergisticallyinhibitatherosclerosisinapolipoproteinemice